Testosterone Isn't Only a Men's Hormone: What Research Shows for Women
Most people think of testosterone as a male hormone. Yet women make it too, and it plays a part in desire, arousal and sexual satisfaction. Over the past three decades, researchers have tested testosterone treatment in thousands of women. The results point to one clear benefit, a few open questions, and useful lessons about who is most likely to gain. Here is what the research shows.
Where women's testosterone comes from
In women, testosterone comes from two places. The ovaries make some of it directly [1]. The adrenal glands, two small glands that sit on top of the kidneys, make "precursor" hormones such as DHEA (dehydroepiandrosterone). Precursors do not act like testosterone themselves, but tissues around the body can convert them into active hormones [2].
Levels fall gradually through a woman's reproductive years, long before menopause [3]. Natural menopause itself changes testosterone levels relatively little, because the ovaries keep producing androgens, the family of hormones that includes testosterone [1]. Surgery that removes both ovaries is different. It causes a much larger drop [1].
What the trials found
The largest body of evidence comes from a 2019 review that pooled 36 randomised trials with 8,480 participants [4]. Randomised trials assign treatment by chance and compare it with a placebo (a dummy treatment) or another therapy. This makes them the most reliable kind of study. In women after menopause, testosterone improved sexual desire, arousal, orgasm, pleasure, responsiveness and self-image. It also reduced sexual concerns and distress [4].
In the same year, a panel representing international menopause, hormone and sexual-health societies reviewed this evidence together. Their joint statement concluded that testosterone, given at levels similar to those a woman has before menopause, improves sexual function in postmenopausal women with low desire. On average, women had about one more satisfying sexual experience per month than with placebo, along with less distress [3].
These benefits were seen mainly in women with a condition called hypoactive sexual desire disorder, or HSDD. HSDD means persistently low sexual desire that causes a woman real distress [2,3]. The panel named HSDD as the only use of testosterone in women that solid evidence currently supports [3].
One extra satisfying experience a month may sound modest. But distress tells a fuller story. In two large trials of a testosterone skin patch in women whose ovaries had been removed, sexual distress fell by about two-thirds with testosterone, compared with 40 to 48% with placebo [2]. For a woman whose low desire troubles her, that difference can matter.
Why the right level matters
A 2014 US trial helps explain why the level matters. Researchers gave 71 women who had had a hysterectomy (removal of the uterus) one of several strengths of testosterone, or a placebo, for 24 weeks. These women were not chosen for low desire. Clear gains in desire, sexual activity and muscle appeared only in the highest-strength group, whose testosterone rose well above the normal female range. At levels within the female range, these women saw no significant change [1].
The lesson is that testosterone is not a "more is better" hormone. Guidelines favour keeping levels within the range a woman naturally has before menopause, and advise against forms that push levels higher [2,3]. How it is taken matters too. Testosterone tablets worsened cholesterol, while forms used through the skin had a neutral effect [3,4].
A blood test alone cannot pick out who will benefit. No testosterone level separates women with and without sexual difficulties, and a woman's level before treatment did not predict her response [2,3].
Who may benefit
On current evidence, the women most likely to benefit are those who:
are past menopause, whether it came naturally or after surgery [3]
have low sexual desire that causes them distress [3]
have had other possible causes looked at first, such as physical health, mood, stress and relationship difficulties [3]
For women who have not yet reached menopause, there is not yet enough data to guide treatment [3].
What testosterone has not been shown to do
Testosterone is sometimes promoted for energy, mood, memory, muscle and bone. At normal female levels, the trials do not yet support these uses. The panel found no effect on general wellbeing or low mood, and too little evidence on memory [3]. No clear effect on bone density, muscle, strength or body fat was seen [3,4]. Knowing this helps women set realistic expectations.
The limits of the evidence
The evidence has real gaps. Trials were mostly short, and data beyond 24 months are lacking [2,3]. Women at high risk of heart disease were left out, and most participants were also taking estrogen [3]. So long-term effects on the heart and breast are still unknown [3]. Not every trial was positive: two large trials of one testosterone gel found no benefit over placebo [2]. Some women had mild acne or extra hair growth, and the review noted a small average weight gain. No serious side effects were recorded in the trials [3,4].
What to talk about with your doctor before starting
Whether your symptoms fit HSDD, and what else might be playing a part [3].
Your personal and family history, including breast cancer and heart disease [3].
Which form of testosterone suits you. Your doctor sets the dose.
How your progress and hormone levels will be checked over time, so they stay within the female range [2,3].
When to stop. Guidelines suggest judging the response over a few months and stopping if there is no benefit [2,3]. If treatment helps, symptoms often return after stopping [2].
Physicians who focus on optimal hormone levels look at testosterone alongside the body's other hormones, never in isolation. You can read more on our Hormone Health page.
Reviewed by Dr. Panapon Lumdee, MD · Last reviewed: 17 November 2026
References
Huang G, Basaria S, Travison TG, Ho MH, Davda M, Mazer NA, et al. Testosterone dose-response relationships in hysterectomized women with and without oophorectomy: effects on sexual function, body composition, muscle performance and physical function in a randomized trial. Menopause. 2014;21(6):612-23. doi:10.1097/GME.0000000000000093
Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510. doi:10.1210/jc.2014-2260
Davis SR, Baber R, Panay N, Bitzer J, Cerdas Perez S, Islam RM, et al. Global consensus position statement on the use of testosterone therapy for women. J Clin Endocrinol Metab. 2019;104(10):4660-6. doi:10.1210/jc.2019-01603
Islam RM, Bell RJ, Green S, Page MJ, Davis SR. Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes Endocrinol. 2019;7(10):754-66.



Comments